No Data
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $57
Arvinas Holding Company: Strategic Pipeline Advancements and Promising Clinical Developments Justify Buy Rating
Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure
Express News | Arvinas: Vepdegestrant to Be Combined With Pfizer's Cdk4 Inhibitor Atirmociclib in a First-Line Phase 3 Trial Planned to Initiate in 2025
Express News | Arvinas Inc - Topline Data From Veritac-2 Phase 3 Trial Expected in 1Q25
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials With Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update